Compare ResMed Inc. (RMD) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wells Fargo & Co — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 7.8× ResMed Inc.'s market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Wells Fargo & Co for 88 Days on average.
| RMD | WFC | |
|---|---|---|
Market Cap | $31.89B | $248.06B |
Volume | 618,314 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $277.88 | $96.40 |
52-Week Low | $182.82 | $73.42 |
Typical Hold Time | 51 Days | 88 Days |
Enterprise Value | $31.24B | $503.91B |
Dividend Yield | 1.16% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Wells Fargo (WFC) trades at $83.55, up 4.1% today, showing strong momentum despite a bearish technical signal. The stock offers attractive valuation with P/E of 11.92 and P/B of 1.5, supported by improving profitability with net margin reaching 25.97% in 2025. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 2026 earnings on October 13th. The company maintains solid fundamentals with $21.34B net income and 13.13% ROE, though cash flow volatility remains a concern.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (18.6% upside) and strong institutional support. However, investors face risks from inconsistent earnings performance (two recent misses), regulatory uncertainty from Fed stress test changes, and volatile cash flow patterns. The stock's technical weakness contrasts with fundamental strength, creating potential for convergence if upcoming earnings beat expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
